Canadian Cancer Trials Group Bulletins


Canadian Cancer Trials Group SC.23 Results Highlighted at ASTRO

Results of Canadian Cancer Trials Group SC.23 show that dexamethasone lowers the rate of pain flare in cancer patients with bone metastases undergoing radiation therapy for symptom control.

These results were presented by Canadian Cancer Trials Group SC.23 trial co-chair, Dr. Edward Chow from Sunnybrook Health Sciences Centre in Toronto, at the American Society for Radiation Oncology (ASTRO) Annual Meeting in San Antonio on October 18, 2015. Dr. Alysa Fairchild from the Cross Cancer Institute in Edmonton, SC.23 co-chair, then presented these same results the next day as part of ASTRO's press program.

You can view Dr. Fairchild's slides and the SC.23 press release by using these links:

Canadian Cancer Trials Group SC.23 is also highlighted on the Canadian Cancer Trials Group's website ....

These results were also published in The Lancet Oncology ...

Congratulations to Drs. Chow and Fairchild, and thanks to all participating centres, staff and patients for their participation in this study.